Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed 3
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 2014E 2015E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 19th Feb, paid: 24th Mar more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +10.9%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2013, AstraZeneca plc revenues decreased 8% to $25.71B. Net income decreased 59% to $2.56B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects As Reported Selling, General & Admin Exp increase of 24% to $12.21B (expense), Other operating income and expense decrease of 39% to $595M (income). more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score
B+
B+

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Dec '13) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: $61.2 (-3.61% below Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: -7.2% ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
34 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 3 8 16 3 4

Named Brokers and Analysts
Jefferies & Company, Inc. Jeffrey Holford , Credit Suisse Luisa Hector , SEB Equities Lars Hevreng , Leerink Partners LLC Seamus Fernandez , Sanford Bernstein Tim Anderson , Danske Markets Martin Parkhøi Mattias Häggblom Thomas Bowers , Jefferies International Ltd , Seymour Pierce , Panmure Gordon Savvas Neophytou , Carnegie Investment Bank AB Kristofer Liljeberg , Redeye , Natixis Philippe Lanone Beatrice Muzard , Collins Stewart & Co , Swedbank Markets Johan Unnerus , Nordea Markets Erik Hultgård , Davy , CA Cheuvreux , Macquarie Research , Societe Generale Stephen McGarry , Handelsbanken Capital Markets Peter Sehested , WestLB Equity Markets , Pareto Securities AS Yilmaz Mahshid , Berenberg Alistair Campbell , DZ Bank , Helvea SA Odile Rundquist , Kepler Cheuvreux Fabian Wenner, PhD , Charles Stanley Rae Ellingham , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Matrix Corporate Capital LLP , Liberum Naresh Chouhan , Alphavalue Armelle Moulin ,

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca’s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Directors: Pascal Soriot (CEO) 54, Marc Dunoyer (CFO) , Lynn Tetrault (Exec. VP) , Ruud Dobber (Exec. VP) , Paul Hudson (Exec. VP) , Bahija Jallal (Exec. VP) , Mark Mallon (Exec. VP) , Briggs Morrison (Exec. VP) , Menelas Pangalos (Exec. VP) , David Smith (Exec. VP) ,

No. of Employees: 51,700 No. of Shareholders: n/a


Last Annual December 31st, 2013
Last Interim December 31st, 2013
Shares in Issue 1,261,295,534
Free Float 1.26bn (99.8%)
ISIN GB0009895292

AZN Share Price Performance AZN Quote
3781.5p
23.0  0.6%
Traded 4:36pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Thursday 24th April, 2014
Q1 2014 AstraZeneca PLC Earnings Release
Thursday 24th April, 2014
AstraZeneca PLC Annual Shareholder Meeting
Thursday 31st July, 2014
Q2 2014 AstraZeneca PLC Earnings Release
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Release

Recent ↓
Monday 10th March, 2014
AstraZeneca PLC at EBD BIO-Europe Spring
Tuesday 4th March, 2014
AstraZeneca PLC at Credit Suisse Healthcare Conference
Monday 3rd March, 2014
AstraZeneca PLC at Cowen Health Care Conference
Monday 24th February, 2014
AstraZeneca PLC at Citi Global Healthcare Conference (1:1 meetings)
Wednesday 19th February, 2014
Dividend For AZN.L
Wednesday 19th February, 2014
Dividend For AZN
Wednesday 19th February, 2014
Dividend For AZN.BA
Thursday 6th February, 2014
Full Year 2013 AstraZeneca PLC Earnings Conference Call
Thursday 6th February, 2014
Full Year 2013 AstraZeneca PLC Earnings Release
Wednesday 15th January, 2014
AstraZeneca PLC at JPMorgan Healthcare Conference


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy AZN

Access AZN Analytics Now!

FREE TRIAL or TAKE THE TOUR